Skip to main content

REVIEW article

Front. Pharmacol.
Sec. Cardiovascular and Smooth Muscle Pharmacology
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1453825

Tirzepatide's Innovative Applications in the Management of Type 2 Diabetes and Its Future Prospects in Cardiovascular Health

Provisionally accepted
Jingqi Yang Jingqi Yang 1Yuncheng Gu Yuncheng Gu 1Huaigang Chen Huaigang Chen 1,2Hong Wang Hong Wang 1Lang Hong Lang Hong 1Bin Li Bin Li 1Liu Yang Liu Yang 1*
  • 1 Jiangxi provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, China
  • 2 Jiangxi Medical College, Nanchang University，, Nanchang, China

The final, formatted version of the article will be published soon.

    Tirzepatide, a novel GLP-1/GIP dual receptor agonist, shows significant advantages in glycemic management and weight control. By summarizing the results of the SURMOUNT and SURPASS clinical trials, we evaluate the efficacy and safety of tirzepatide in reducing blood glucose and weight. These trials indicate that tirzepatide significantly lowers HbA1c levels (with a maximum reduction of 2.24%) and promotes weight loss (up to 11.2 kg) with good tolerability. However, there are still some challenges in its clinical application, including high treatment costs and gastrointestinal discomfort. Additionally, the safety and efficacy of tirzepatide in special populations, such as patients with renal impairment, require further investigation. Future large-scale clinical trials, such as SURPASS-CVOT and SUMMIT, are expected to further verify the long-term benefits of tirzepatide in cardiovascular health management, providing stronger evidence for its comprehensive treatment of diabetes and its complications

    Keywords: tirzepatide, GLP-1/GIP dual receptor agonist, Glycemic management, weight control, Cardiovascular health management

    Received: 24 Jun 2024; Accepted: 13 Aug 2024.

    Copyright: © 2024 Yang, Gu, Chen, Wang, Hong, Li and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Liu Yang, Jiangxi provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.